Solara Active Pharma Sciences Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-ac3964c680ca51dcb51bc6e8.pdf

Key Takeaways


Base Business Performance

Rao: "That depends on how long the crisis lasts, so that's beyond us. But we have learned to live with the crisis and make the most of the situation."

Ibuprofen: Recovery & Uncertainty

Rao: "There are players in India who are increasing their capacity... And then on the other side you have players in the Western world who we hear are shutting down their facilities. So this is a time where we are just waiting and watching."

Strategic Review: Ibuprofen, Vizag & CRAMS

Rao: "Nothing has changed in our options... One is repurposing the plant from being a single product dedicated facility into a multi-product facility... And of course, the other option is the eternal option of finding an appropriate buyer who can take the facility."

Balance Sheet & Cash Flows


Regulatory & Pipeline Progress


Margin Outlook & Operating Leverage

Rao: "I'd be cautiously optimistic. I would say we've turned around if we can get another two quarters in line with the current quarter or better than the current quarter."

Guidance & Commitments

CommitmentSpecificsTimeline
Strategic review outcomeDecision on ibuprofen plant (repurpose or sell), Vizag, and CRAMS12 weeks from call date
DMF filingsThree more DMFs in FY27, totaling five for the yearBy FY27 end
DMF filing trajectoryTwo to four DMFs per yearNext three years
Base business gross marginSustain 52–55% range (adjusted for unrecovered input costs)Ongoing; headwinds persist 1–2 more quarters
Operating cost baseRemain flattish in current range (±2–3%)Ongoing
Net debt to EBITDARemain ~1.8xMedium term
Turnaround confirmationTwo more quarters in line with or better than Q2 FY27Two quarters

Key Metrics

MetricQ2 FY27
Revenue₹418 crores, up 33% YoY
EBITDA₹77 crores, up 118% YoY
EBITDA margin18.4%, up ~720 bps YoY and ~200 bps QoQ
PAT₹28.5 crores, vs loss of ~₹10 crores in Q2 FY26; highest in five years
EPS₹5.92 per share; adjusted for exceptional item would have been ~₹1 higher
Gross margin47.2%, ~200 bps lower YoY due to West Asia crisis input costs
Base business revenue₹327 crores, up 37% YoY; third consecutive quarter above ₹300 crores
Base business EBITDA margin23.6%, up ~440 bps YoY
Base business gross margin50%+, slightly lower than previous quarters due to product mix and input costs
Ibuprofen business revenue₹91 crores, up 21% YoY and 18% QoQ
Ibuprofen EBITDANear breakeven, vs ~₹9 crore loss in Q1 FY27; loss margin was ~21% two quarters ago
Ibuprofen gross margin36%, recovered driven by changing market dynamics
Net debt~₹500 crores, down from ₹614 crores as of Mar 2026
Net debt to EBITDA~1.8x, improved from 3.2x last year
H1 FY27 EBITDA~₹140 crores, up 51% YoY; margin 17.5% vs ~15% in H1 FY26
H1 FY27 PAT~₹45 crores, vs near breakeven in H1 FY26
Regulated markets revenue share~78% of revenues
DMF filings in FY272 filed (Q1 and Q2), targeting 5 for the full year
Exceptional loss (Vizag equipment sale)₹4.5 crores, one-off monetization of unutilized ibuprofen assets